Day 1 :
The Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY USA
Keynote: Impact of nanobiotechnology on the future of medicine (Nanomedicine): The road towards precision medicine
Time : 10:15-11:00
Shaker A Mousa finished his PhD from Ohio State University, College of Medicine, Columbus, OH and Post-doctoral Fellowship, University of Kentucky, Lexington KY. He also received his MBA from Widener University, Chester, PA. He is currently an endowed tenure Professor and Executive Vice President and Chairman of the Pharmaceutical Research Institute and Vice Provost for Research at ACPHS. Prior to his academic career, he was a senior Scientist and fellow at The DuPont Pharmaceutical Company for 17 years, where he contributed to the discovery and development of several FDA approved and globally marketed diagnostics and therapeutics. He holds over 350 US and International Patents discovering novel anti-angiogenesis strategies, antithrombotics, anti-integrins, anti-cancer, and non-invasive diagnostic imaging approaches employing various nanotechnology platforms. His has published more than 1,000 journal articles, book chapters, published patents, and books as editor and author. He is a member of several NIH study sections, and the Editorial Board Member of several high impact Journals. His research has focused on diagnostics and therapeutics of angiogenesis-related disorders, thrombosis, vascular and cardiovascular diseases.
Over the past few years, evidence from the scientific and medical communities has demonstrated that nanotechnology and nanomedicine have tremendous potential to profoundly impact numerous aspects of cancer and other disorders in term of early diagnosis and targeted therapy. The utilization of nanotechnology for the development of new nano-carrier systems has the potential to offer improved chemotherapeutic delivery through increased solubility and sustained retention. One of the major advantages of this cutting edge technology is its unique multifunctional characteristics. Targeted delivery of drug incorporated nanoparticles, through conjugation of tumor-specific cell surface markers, such as tumor-specific antibodies or ligands, which can enhance the efficacy of the anticancer drug and reduce the side effects. Additionally, multifunctional characteristics of the nano-carrier system would allow for simultaneous imaging of tumor mass, targeted drug delivery and monitoring (Theranostics). A summary of recent progress in nanotechnology as it relates specifically to nanoparticles and anticancer drug delivery will be reviewed. Nano Nutraceuticals using combination of various natural products provide a great potential in diseases prevention. Additionally, various Nanomedicine approaches for the detection and treatment of various types of organ specific delivery, vascular targeting, and vaccine will be briefly discussed.
Western University, Canada
Time : 11:15-12:00
Mahi R Singh received PhD (1976) degree from Banaras Hindu University, Varanasi in Condensed Matter Physics. After that, he was awarded an Alenxander vonrnHumbold Fellow in Stuttgart University, Germany from 1979 to 1981. Currently, he is Professor in the same university. He was a visiting Professor at University ofrnHouston. He also worked as a Chief Researcher at CRL HITACHI, Tokyo and he was a visiting Professor and Royal Society Professor at University of Oxford, UK.rnHe was the Director of the Centre of Chemical Physics and Theoretical Physics Program at Western. He has worked in many fields of research in science and technologyrnincluding nanoscience, nanotechnology, nanophotonics, optoelectronics, semiconductors structures, high temperature superconductors, nanophotonics, rnplasmonics, polarotonics and nanoscience and technology.
We study new types of the sensing mechanism for cancers sensing from quantum dots (QDs) and metallic nanoparticlernhybrids. It is well known that the metallic nanoparticles have negative electric permittivity which leads to the formationrnof new particles called surface plasmon polaritons which may generate exceptionally strong localized electromagnetic fields.rnOn the other hand quantum dotes have electronic particles called exactions. The QDs interact with surface plasmon polaritonsrnof the metallic nanoparticles. We have calculated the energy exchange between the QDs and the nanoparticles in the presencernof exciton-surface plasmon interaction. It is found that energy transfer is enhanced in the presence of the nanoparticles whenrnthe excitons and surface plasmon frequencies are resonant. The energy transfer can be switched on and off by applying thernexternal fields such as lasers or stress fields. The energy transfer can be used as sensing mechanism for cancer treatment. Thernpresent results can be used to make new types of nanoscale cancer detection devices based on these hybrid nanostructures.